Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02683525
Recruitment Status : Active, not recruiting
First Posted : February 17, 2016
Last Update Posted : July 19, 2019
Sponsor:
Information provided by (Responsible Party):
Sherif S. Farag, Indiana University School of Medicine

Brief Summary:

Primary Objective

Evaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplantation and receiving standard sirolimus and tacrolimus GvHD prophylaxis.

Secondary Objectives

The following descriptive secondary objectives will be studied:

  1. Describe the tolerability and potential toxicity of sitagliptin.
  2. Describe the cumulative incidence of grades II-IV acute GvHD by day +100.
  3. Describe the cumulative incidence of grades III-IV acute GvHD.
  4. Describe the engraftment kinetics of absolute neutrophil count and platelets.
  5. Describe the incidence of infections occurring during the 100 days post-transplant.
  6. Describe non-relapse mortality (NRM) at day +30, +100, and 1 year post-transplant.
  7. Describe overall survival.
  8. Describe the incidence of chronic GvHD.
  9. Describe the cumulative incidence of relapse of the primary hematological malignancy.

Condition or disease Intervention/treatment Phase
Graft vs Host Disease Hematopoietic Stem Cell Transplantation Drug: Sitagliptin Phase 2

Detailed Description:

This is an open label phase II study in patients undergoing allogeneic hematopoietic stem cell transplantation and receiving standard sirolimus and tacrolimus GvHD prophylaxis. Although the myeloablative preparative regimen is not prescribed, it is anticipated that most patients will receive total body irradiation (TBI) plus etoposide (TBI/VP16), or high-dose thiotepa plus cyclophosphamide according to institutional standards. Regardless of the preparative regimen, all patients will receive the following regimen for GvHD prophylaxis, which includes the study drug sitagliptin:

Day -3: Tacrolimus is initiated on day -3 with a suggested starting dose of 0.01 mg/kg/day IV as a continuous infusion and them modified to target a serum level of 5-10 ng/ml. Serum levels should be monitored at least twice weekly until discharge, then at times of outpatient clinic visits according to institutional practice. Tacrolimus may be switched to PO dosing when the patient is able to tolerate oral intake satisfactorily. Note that concurrent use of agents such as itraconazole, voriconazole or fluconazole (at doses > 200 mg) may inhibit the metabolism of tacrolimus, and thus increase tacrolimus levels. Initial dosing may be decreased in order to account for increased levels related to use of 'azole' agents. In addition, it is recommended to check tacrolimus levels twice weekly when these agents are initiated concurrently.

Sirolimus is started on day -3 with a suggested loading dose of 1 mg PO, then 0.5 mg/day PO single dose from day -2 to maintain a target serum level of 5-10 ng/ml. Serum levels should be monitored twice weekly until discharge, then at times of outpatient clinic visits according to institutional practice. Initial dosing may be decreased in order to account for increased levels related to use of 'azole' agents.

Day -1: Sitagliptin 600 mg q 12 hours PO starting on Day -1 to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.

In the absence of acute GvHD, begin tapering of both tacrolimus and sirolimus on Day +100 as tolerated with a goal of stopping by Day +180. The rate of taper may be adjusted for presence of signs and symptoms of GvHD. Mycophenolate mofetil may be substituted for tacrolimus or sirolimus if any toxicity related to these drugs arises (e.g., renal failure, hemolytic microangiopathy, allergic rash, etc.).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Actual Study Start Date : February 3, 2016
Actual Primary Completion Date : February 13, 2019
Estimated Study Completion Date : February 28, 2020


Arm Intervention/treatment
Experimental: Sitagliptin
Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
Drug: Sitagliptin
600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: +100 days after transplant ]
    Summary of all adverse events and Non-hematological toxicity (other than nausea, vomiting, non-GvHD related diarrhea, and electrolyte abnormalities) will be graded and described according to The National Cancer Institute Common Terminology Criteria for Adverse events (CTCAE) version 4.0 (http://ctep.cancer.gov), and will be described in terms of frequency. Attribution to sitagliptin will also be described.


Secondary Outcome Measures :
  1. Cumulative incidence of grade II-IV acute GvHD [ Time Frame: +100 days ]
    Non-hematological toxicity (other than nausea, vomiting, non-GvHD related diarrhea, and electrolyte abnormalities) will be graded and described according to The National Cancer Institute Common Terminology Criteria for Adverse events (CTCAE) version 4.0 (http://ctep.cancer.gov), and will be described in terms of frequency. Attribution to sitagliptin will also be described.

  2. Cumulative incidence of grade III-IV acute GvHD [ Time Frame: +100 days ]
    Non-hematological toxicity (other than nausea, vomiting, non-GvHD related diarrhea, and electrolyte abnormalities) will be graded and described according to The National Cancer Institute Common Terminology Criteria for Adverse events (CTCAE) version 4.0 (http://ctep.cancer.gov), and will be described in terms of frequency. Attribution to sitagliptin will also be described.

  3. Time to engraftment of neutrophils [ Time Frame: +3 days ]
    Time from day 0 of transplant to the first of three consecutive days after transplantation during which the ANC is greater than or equal to 0.5 x109/l

  4. Time to engraftment of platelets [ Time Frame: +7 days ]
    Time from day 0 to the first of seven consecutive days after transplantation during which the platelet count is greater than or equal to 20 x109/l without transfusion.

  5. Incidence of types infections [ Time Frame: +100 days ]
    Infections (i.e., viral, bacterial, fungal, etc.) will be tabulated and described

  6. Non-relapse mortality (NRM) [ Time Frame: 1 year ]
  7. Overall survival [ Time Frame: 1 year ]
  8. Incidence of chronic GvHD [ Time Frame: 1 year ]
    Patients surviving at least 100 days will be evaluable for chronic GvHD. The cumulative incidence of chronic GvHD (total, and mild, moderate, severe) will be described using deaths from causes other than chronic GvHD considered as a competing risk.

  9. Cumulative incidence of relapse of the primary hematological malignancy [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

A. Patients with any of the following hematologic malignancies:

  1. Acute myeloid leukemia (AML) with any of the following:

    1. In first remission (CR1) with intermediate risk or high-risk cytogenetic and/or molecular features.
    2. Patients in second or subsequent complete remission (CR2, CR3, etc.).
    3. Primary refractory or relapsed AML with no more than any one of the following adverse additional features according to modified CIBMTR criteria:49

      • Duration of first CR < 6 months
      • Poor risk cytogenetics or molecular features (FLT-3 internal tandem duplication (ITD); complex karyotype with ≥3 clonal abnormalities, 5q-/-5, 7q-/-7, 11q23 abnormalities, inv(3), monosomal karyotype)
      • Circulating peripheral blood blasts at time of enrollment
      • Karnofsky performance status <90%
  2. Acute lymphoblastic leukemia (ALL) with any of the following:

    1. In CR1 or subsequent complete remission (CR2, CR3, etc.)
    2. Primary refractory or relapsed ALL with no more than one of the following adverse features according to modified CIBMTR criteria:49

      • Second or subsequent relapse
      • Bone marrow blasts >25% at time of enrollment
      • Age >40 years
  3. Myelodysplasia with any of the following features:

    1. Refractory anemia with excess blasts type I (5-10% blasts) or II (11-20% blasts) in the bone marrow (RAEB I and II)
    2. Refractory cytopenia with multilineage dysplasia (RCMD) and poor risk cytogenetics (i.e., chromosome 7 abnormalities or complex karyotype with at least 3 abnormalities per clone)
  4. Chronic myelogenous leukemia (CML) with one of the following criteria:

    1. Accelerated phase, defined by any of the following:

      • Blasts 10-19% in peripheral blood white cells or bone marrow
      • Peripheral blood basophils at least 20%
      • Persistent thrombocytopenia (<100 x 109/l) unrelated to therapy, or persistent thrombocytosis (>1000 x 109/l) unresponsive to therapy
      • Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy
      • Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase)
    2. Chronic phase provided a complete hematologic remission was not achieved by 3 months or a complete cytogenetic remission by 18 months and the patient had received at least 2 tyrosine kinase inhibitors
  5. Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, who also have one of the following criteria:

    1. Failure to achieve complete remission to primary induction therapy
    2. Relapsed and refractory to at least one line of salvage systemic therapy
    3. Failed stem cell collection
  6. Patients with Hodgkin's lymphoma meeting one of the following criteria:

    1. Primary refractory (failure to achieve complete remission to primary induction therapy)
    2. Relapsed and refractory to at least one line of salvage systemic therapy
    3. Failed stem cell collection

B. Patient age ≥ 18 to ≤ 60 years

C. Karnofsky Performance status ≥ 70%

D. Patients must also receive a full myeloablative preparative regimen (Patients treated with either total body irradiation (TBI)-based or high-dose chemotherapy only regimens are eligible other than high-dose busulfan containing regimens or regimens that include anti-thymocyte globulin or other T cell depleting antibodies)

E. Patients receiving allogeneic peripheral blood stem cell (PBSC) grafts from HLA-matched (5/6 and 6/6 matches) siblings or from well matched unrelated donors (9/10 or 10/10 matches at HLA-A, B, C, DRB1 and DQB1 by high resolution typing) are included. All grafts will be unmanipulated (i.e., no T cell depleted or CD34 selected grafts).

F. No uncontrolled bacterial, viral or fungal infection at time of enrollment defined as currently taking medication and progression of clinical symptoms

G. No HIV disease (Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies)

H. Non-pregnant and non-nursing

I. Required baseline values within 60 days prior to admission:

  1. LVEF ≥ 45%
  2. DLCO ≥ 50% of predicted (corrected for hemoglobin)

J. Required baseline laboratory values within 16 days prior to admission:

  1. Estimated creatinine clearance ≥60 ml/min
  2. Serum total bilirubin ≤ 2 x upper limit of normal value (ULN)
  3. AST and ALT ≤ 2 x ULN (unless determined by treating physician to be related to underlying malignancy)

K. Signed written informed consent (Patient must be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent)

L. Patients must otherwise fulfill institutional criteria for eligibility to undergo myeloablative allogeneic stem cell transplantation

EXCLUSION CRITERIA:

A. Symptomatic uncontrolled coronary artery disease or congestive heart failure

B. Severe hypoxemia with room air PaO2 < 70, supplemental oxygen dependence, or DLCO < 50% predicted

C. Patients with active central nervous system involvement

D. Prior allogeneic or autologous hematopoietic stem cell transplant in past 12 months

E. Patients with diabetes mellitus requiring insulin secretagogues and/or insulin

F. Patients with hypertriglyceridemia with serum triglyceride level ≥500 mg/d (lipid lowering drugs may be used to control level)

G. Patients with a history of pancreatitis

H. Patients with symptomatic cholelithiasis

I. Patients with a current dependence on alcohol (characterized by a physical addiction to alcohol that interferes with physical or mental health, and social, family or job responsibilities)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02683525


Locations
Layout table for location information
United States, Indiana
Indiana University Health Hospital
Indianapolis, Indiana, United States, 46202
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Sherif S. Farag
Investigators
Layout table for investigator information
Principal Investigator: Sherif Farag, MD, PhD Indiana University School of Medicine, Indiana University Simon Cancer Center

Layout table for additonal information
Responsible Party: Sherif S. Farag, Lawrence H. Einhorn Professor of Oncology, Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT02683525     History of Changes
Other Study ID Numbers: IUSCC-0522
First Posted: February 17, 2016    Key Record Dates
Last Update Posted: July 19, 2019
Last Verified: July 2019
Keywords provided by Sherif S. Farag, Indiana University School of Medicine:
Allogeneic
Sitagliptin
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Sitagliptin Phosphate
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action